Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Apr 25;5(5):e452. doi: 10.1097/TXD.0000000000000894

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2019 The Author(s). Transplantation Direct. Published by Wolters Kluwer Health, Inc.

This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

PMC Copyright notice

FIGURE 1. — Clinical follow-up of a patient with corneal neovascularization treated with fine-needle vessel cauterization and bevacizumab application before penetrating keratoplasty. In this eye, no graft rejection was observed. A, Herpetic corneal scar with corneal neovascularization in the lower corneal quadrants before fine-needle vessel cauterization and bevacizumab application. B, Corneal scar without neovascularization 6 mo after fine-needle cauterization and bevacizumab application (1 day before penetrating keratoplasty). C, Clear cornea without any signs of allograft rejection 24 mo after penetrating keratoplasty.